Cogent Biosciences' SUMMIT trial showed strong results for its drug, leading Jefferies to raise its price target.
1 report, 1 independent
Updated Jul 17
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cogent Biosciences' SUMMIT trial showed strong results for its drug, leading Jefferies to raise its price target.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cogent Biosciences (United States)
company in Waltham, United States
Nothing else this week.
-
Donald Trump
American businessman and politician (born 1946), President of the United States (2017–2021; since 2025)
Related events
Coverage
Newest first; wire copies grouped- Insider MonkeyJefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating Cogent Biosciences, Inc. (NASDAQ:COGT) is one of the 10 Best Small-Cap Stocks to Buy According to Billionaires. On July 7, Jefferies in